Articles Tagged With: mortality
-
Total Steps vs. How You Get Them and the Risk of Cardiovascular Events
In a large U.K. Biobank study of subjects who performed a one-week determination of steps/day, those who achieved < 8,000 steps/day were categorized by the duration of their step acquisition periods and were followed for a mean of eight years. All-cause mortality and the development of cardiovascular disease (CVD) were greater in those with short step acquisition periods (< 5 minutes) as compared to those with longer periods (> 15 minutes). Thus, longer step acquisition bouts are more effective in reducing mortality and CVD in those with less-than-ideal total daily step counts.
-
Efficacy of Adding Aspirin to OACs for CAD Patients
A randomized, placebo-controlled trial of adding aspirin to oral anticoagulant therapy in patients with chronic coronary artery disease at high risk of atherothrombotic complications and major bleeding was stopped early because aspirin increased the risk of all-cause mortality. In addition, aspirin was associated with an increase in atherothrombotic complications and major bleeding.
-
Contemporary Cardiovascular Disease Deaths in Asian Americans
An analysis of a Centers for Disease Control and Prevention database has shown the cardiovascular disease mortality rate is higher in Asian Americans than in non-Asian Americans and that this excess mortality is particularly prevalent in Filipino Americans.
-
DanGer Shock Trial Post-Hoc Analysis: Microaxial Pump Risks May Outweigh Benefits
In this post-hoc analysis of the DanGer Shock trial, patients in the highest quartile of age appeared to have higher mortality compared with younger patients, suggesting less benefit from routine application of the microaxial flow pump in older patients with acute myocardial infarction-related cardiogenic shock.
-
Durability of Mitral Valve Repair for Degenerative Mitral Regurgitation
A large, single-center, contemporary long-term follow-up of degenerative mitral valve disease patients undergoing mitral valve repair surgery has shown that 30-day post-operative mortality is < 1% and a median almost nine-year follow-up survival is 90%. Somewhat worse outcomes were observed in those with preoperative symptoms, reduced left ventricular function, atrial fibrillation, and isolated anterior leaflet disease.
-
Validation of the New American Heart Association’s PREVENT Equations
An analysis of the accuracy of the new American Heart Association PREVENT Equations for predicting 10-year cardiovascular disease mortality in the National Health and Nutrition Examination Survey population has shown excellent discrimination with only modest underprediction and supports its use vs. the pooled cohort equation, which is the current standard.
-
Mortality in Sepsis Patients Treated with Piperacillin-Tazobactam vs. Cefepime
A retrospective cohort study that included more than 7,000 patients with sepsis and no clear indication for anti-anaerobic coverage found receipt of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared to cefepime.
-
Age Is Not a Risk Factor for the Oldest Patients with COVID-19
Are patients hospitalized for COVID-19, who are younger than 65 years of age, at less risk of serious outcomes than are similar patients who are older than 85 years of age? New research provides an answer that may surprise many clinicians: Metabolic syndrome measures are a major predictor of outcomes, but chronological age is not a relevant risk factor for poor outcomes attributed to COVID-19.
-
Rapid Reversal of Anticoagulation Reduces Mortality from Intracerebral Hemorrhage
Because the numbers of patients with primary intracerebral hemorrhage are far lower than those with ischemic stroke, it has been difficult to accumulate a large enough number of patients to clearly analyze the relationship between the time of the hemorrhage and the time to treatment. We need to answer the important question: Does rapid treatment result in a better outcome?
-
High-Mortality Cryptococcosis Infection After COVID-19
A survey initiated by the Mycoses Study Group identified 69 cases of cryptococcosis following COVID-19 infection. The mortality rate was 59%, with cases in both immunocompromised and immunocompetent individuals.